NBRV Nabriva Therapeutics plc

2.29
+0.03  (+1%)
Previous Close 2.26
Open 2.29
Price To Book 3.88
Market Cap 167,997,629
Shares 73,361,410
Volume 213,088
Short Ratio
Av. Daily Volume 1,685,639

NewsSee all news

  1. Nabriva Therapeutics to Present at the 2019 Cantor Global Healthcare Conference

    DUBLIN, Ireland and KING OF PRUSSIA, Pa., Sept. 18, 2019 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative

  2. Nabriva Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    DUBLIN, Ireland, Sept. 06, 2019 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat

  3. Nabriva Therapeutics Earns $5 Million Milestone Payment under its License Agreement with Sinovant Sciences

    DUBLIN, Ireland and KING OF PRUSSIA, Pa., Sept. 06, 2019 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative

  4. Nabriva Therapeutics to Present Data at ASM/ESCMID Conference Demonstrating Utility of Xenleta™ (lefamulin) for Patients with Community-Acquired Bacterial Pneumonia (CABP)

    DUBLIN, Ireland, Sept. 05, 2019 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat

  5. Nabriva Therapeutics to Present at the 17th Annual Morgan Stanley Global Healthcare Conference

    DUBLIN, Ireland and KING OF PRUSSIA, Pa., Aug. 28, 2019 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

FDA approval announced August 19, 2019.
Lefamulin - Intravenous and Oral
Moderate to severe Community Acquired Bacterial Pneumonia (CABP)
CRL issued April 30, 2019. NDA resubmission due early 4Q 2019.
Contepo
Complicated urinary tract infections (cUTI)

Latest News

  1. Nabriva Therapeutics to Present at the 2019 Cantor Global Healthcare Conference

    DUBLIN, Ireland and KING OF PRUSSIA, Pa., Sept. 18, 2019 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative

  2. Nabriva Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    DUBLIN, Ireland, Sept. 06, 2019 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat

  3. Nabriva Therapeutics Earns $5 Million Milestone Payment under its License Agreement with Sinovant Sciences

    DUBLIN, Ireland and KING OF PRUSSIA, Pa., Sept. 06, 2019 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative

  4. Nabriva Therapeutics to Present Data at ASM/ESCMID Conference Demonstrating Utility of Xenleta™ (lefamulin) for Patients with Community-Acquired Bacterial Pneumonia (CABP)

    DUBLIN, Ireland, Sept. 05, 2019 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat

  5. Nabriva Therapeutics to Present at the 17th Annual Morgan Stanley Global Healthcare Conference

    DUBLIN, Ireland and KING OF PRUSSIA, Pa., Aug. 28, 2019 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative